Search for: "Jump v State"
Results 3341 - 3360
of 3,652
Sort by Relevance
|
Sort by Date
16 Jul 2008, 6:59 am
It just may be, if David Kopel at VC is correct when he writes: District of Columbia v. [read post]
15 Jul 2008, 2:00 pm
(People v. [read post]
14 Jul 2008, 5:00 am
We've said it before, and we'll say it again: Plaintiffs will now regularly plead that their state law claims against device manufacturers run "parallel" to the FDA's requirements and so are not preempted under Riegel v. [read post]
11 Jul 2008, 3:21 pm
Apotex, Inc. after the jump. [read post]
11 Jul 2008, 12:49 pm
And unlike United States v. [read post]
9 Jul 2008, 10:29 pm
(See AMF, Inc. v. [read post]
8 Jul 2008, 3:03 pm
I'll say a bit more about both of these two difficulties after the jump. [read post]
7 Jul 2008, 8:41 pm
Read the complete statement, after the jump (or just click here). [read post]
3 Jul 2008, 3:13 pm
In addition, If you read the briefs in Kennedy v. [read post]
30 Jun 2008, 6:39 pm
His 20 percentage-point jump to the left in criminal cases likely contributed to his solid 84% concurrence with the majority in all cases, as he and Justice Stevens met in the middle. [read post]
30 Jun 2008, 5:33 pm
USA v. [read post]
30 Jun 2008, 12:18 am
See Ferguson v. [read post]
27 Jun 2008, 2:03 pm
All available filings in the granted cases are available after the jump. __________________ Docket: 07-984 and 07-990 Case name: Coeur Alaska, Inc. v. [read post]
26 Jun 2008, 9:30 pm
Brief amicus curiae of United States (recommending holding of petition pending decision in MetLife v. [read post]
25 Jun 2008, 6:37 pm
Corp. v. [read post]
23 Jun 2008, 2:46 pm
Summaries of the issues and all available certiorari-stage filings in today’s granted cases are available after the jump. [read post]
23 Jun 2008, 3:00 am
Nothing like the problem staring you in the face to jump start a classroom discussion on the separation of powers. [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO: (Managing… [read post]
19 Jun 2008, 12:00 pm
Without preemption, however, state juries are asked to do just that. [read post]
18 Jun 2008, 10:25 pm
Osram Sylvania, Inc. after the jump. [read post]
